Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically recurrent, or advanced NSCLC: Stage IV disease; or Stage IIIB due to malignant pleural effusion is allowed- only if successfully pleurodesed.~* Tumor tissue slides must express phosophorylated pdgf-rB by IHC.~* At least one measurable target lesion as defined by RECIST criteria that has not been irradiated.~* No prior chemotherapy treatment for this disease will be allowed. Patients with brain metastasis will have to be, after appropriate treatment, neurologically stable for at least 1-2 weeks (off steroids) prior to study enrollment.~* ECOG performance status 0-1.~* Meets initial laboratory parameters.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.~Exclusion Criteria~* Any prior treatment with a biologic response modifier or chemotherapeutic agent for this disease.~* Any concomitant malignancy except non-melanoma skin cancer or in-situ carcinoma of the cervix.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to STI571 and/or docetaxel, or other drugs formulated with polysorbate 80 and/or cisplatin.~* Patients with:~  * Contrast allergy.~ * GI bleed ≤ 1 month from study enrollment.~ * Intermittent or chronic oxygen requirements.~ * Pulse oximetry \<90%.~ * Grade 3 dyspnea.~ * History of poorly regulated anticoagulation with warfarin.~ * Edema or fluid retention grade \>1.~ * Neuropathy grade ≥1.~* Uncontrolled inter-current medical illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, ≤3 months myocardial infarction or cardiac arrhythmia.~* Psychiatric illness/social situations that would limit compliance with study requirement or that would prevent informed consent or psychiatric illness/social situations requiring inpatient treatment within the past 3 months.~* Any type of hearing impairment.~* Known HIV infection.~* Receiving other investigational agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).